Krish S. Krishnan - 26 Feb 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role: President and CEO, Director, 10%+ Owner
Signature: /s/ Krish S. Krishnan
Issuer symbol: KRYS
Transactions as of: 26 Feb 2022
Net transactions value: -$290,938
Form type: 4
Filing time: 01 Mar 2022, 20:18:18 UTC
Previous filing: 14 Dec 2021
Next filing: 09 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRYS	Common Stock	Tax liability	$290,938	-4,655	-0.26%	$62.50	1,813,688	26 Feb 2022	Direct	F1, F2
holding	KRYS	Common Stock						1,752,263	26 Feb 2022	By Spouse	F3
holding	KRYS	Common Stock						90,000	26 Feb 2022	By Krishnan Spousal Trust
holding	KRYS	Common Stock						50,000	26 Feb 2022	By Krishan Family Trust	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRYS	Stock Option (Right to Buy)	Award	$0	+50,000		$0.000000	50,000	28 Feb 2022	Common Stock	50,000	$63.55	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents tax withholding upon the vesting of 10,200 shares of restricted stock on February 26, 2022.
F2	The closing price on February 25, 2022 of the Company's common stock on NASDAQ.
F3	Directly beneficially owned by Suma M. Krishnan, the spouse of the reporting person.
F4	Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
F5	The option vests in four equal annual installments beginning on February 28, 2023.